Payment overview · 2025
General Payments
$332.27
18 reported records · 10 companies
Healthcare provider profile · identity verified
Jonnathan David Soltero, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · ORLANDO, FL · NPI 1376068940
Verified facts
What the public records show
CMS Open Payments records show Jonnathan David Soltero, ARNP received $332.27 in general payments during 2025 across 18 reported records.
PFIZER INC. accounted for 29.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $98.74 | 29.7% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $62.60 | 18.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.33 | 9.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.26 | 9.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.90 | 6.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.99 | 6.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.00 | 5.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.28 | 5.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.10 | 5.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.07 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $332.27 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $62.60 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $54.54 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $54.54 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $30.33 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.26 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.26 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.90 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 55 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 40 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 58 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 83 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
50 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
83 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
58 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
46 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
55 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 545 | 218 |
| Losartan Potassium | Losartan Potassium | 335 | 136 |
| Amlodipine Besylate | Amlodipine Besylate | 326 | 130 |
| Gabapentin | Gabapentin | 319 | 126 |
| Levothyroxine Sodium | Levothyroxine Sodium | 272 | 107 |
| Metformin Hcl | Metformin Hcl | 253 | 103 |
| Prednisone | Prednisone | 250 | 202 |
| Lisinopril | Lisinopril | 244 | 98 |
| Tizanidine Hcl | Tizanidine Hcl | 243 | 108 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 240 | 104 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 211 | 186 |
| Fluticasone Propionate | Fluticasone Propionate | 209 | 76 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 206 | 78 |
| Ibuprofen | Ibuprofen | 186 | 97 |
| Famotidine | Famotidine | 183 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 183 | 76 |
| Omeprazole | Omeprazole | 174 | 77 |
| Baclofen | Baclofen | 148 | 69 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 146 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 138 | 55 |
| Trazodone Hcl | Trazodone Hcl | 133 | 54 |
| Diclofenac Sodium | Diclofenac Sodium | 129 | 51 |
| Meclizine Hcl | Meclizine Hcl | 126 | 55 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 118 | 46 |
| Simvastatin | Simvastatin | 115 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 49 |
| Azithromycin | Azithromycin | 111 | 104 |
| Carvedilol | Carvedilol | 110 | 43 |
| Montelukast Sodium | Montelukast Sodium | 105 | 46 |
| Ozempic | Semaglutide | 105 | 35 |
| Meloxicam | Meloxicam | 103 | 41 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 94 | 85 |
| Pioglitazone Hcl | Pioglitazone Hcl | 93 | 34 |
| Ondansetron Hcl | Ondansetron Hcl | 89 | 47 |
| Alendronate Sodium | Alendronate Sodium | 88 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 33 |
| Dicyclomine Hcl | Dicyclomine Hcl | 86 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 83 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 81 | 38 |
| Donepezil Hcl | Donepezil Hcl | 80 | 37 |
| Furosemide | Furosemide | 80 | 50 |
| Glipizide | Glipizide | 77 | 37 |
| Glipizide Er | Glipizide | 71 | 29 |
| Buspirone Hcl | Buspirone Hcl | 68 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 31 |
| Sertraline Hcl | Sertraline Hcl | 62 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 55 |
| Glimepiride | Glimepiride | 59 | 27 |
| Mounjaro | Tirzepatide | 58 | 13 |
| Eliquis | Apixaban | 55 | 21 |
| Clonidine Hcl | Clonidine Hcl | 53 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 32 |
| Clotrimazole | Clotrimazole | 50 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 50 | 16 |
| Allopurinol | Allopurinol | 48 | 19 |
| Trulicity | Dulaglutide | 46 | 16 |
| Ketoconazole | Ketoconazole | 45 | 18 |
| Mupirocin | Mupirocin | 45 | 34 |
| Naproxen | Naproxen | 45 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 41 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 22 |
| Metformin Hcl Er | Metformin Hcl | 42 | 16 |
| Erythromycin | Erythromycin Base | 41 | 36 |
| Finasteride | Finasteride | 41 | 18 |
| Jardiance | Empagliflozin | 40 | 17 |
| Ezetimibe | Ezetimibe | 39 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 37 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 38 | suppressed |
| Hydrocortisone | Hydrocortisone | 38 | 16 |
| Nitroglycerin | Nitroglycerin | 38 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 35 | 17 |
| Alprazolam | Alprazolam | 34 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 33 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | 11 |
| Fenofibrate | Fenofibrate,micronized | 32 | 12 |
| Lactulose | Lactulose | 31 | 21 |
| Atenolol | Atenolol | 30 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 30 | 11 |
| Ciclopirox | Ciclopirox | 29 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | 11 |
| Loperamide | Loperamide Hcl | 28 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Benzonatate | Benzonatate | 27 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | 12 |
| Breyna | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 20 |
| Metronidazole | Metronidazole | 24 | 22 |
| Mirtazapine | Mirtazapine | 23 | 11 |
| Acyclovir | Acyclovir | 22 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | suppressed |
| Potassium Chloride | Potassium Chloride | 21 | 12 |
| Sucralfate | Sucralfate | 21 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | 12 |
| Ondansetron Odt | Ondansetron | 18 | 11 |
| Latanoprost | Latanoprost | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Constulose | Lactulose | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 13 | 12 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Procto-Med Hc | Hydrocortisone | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | 12 |
| Clonazepam | Clonazepam | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Tresiba | Insulin Degludec | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $332.27 · 18 records | PFIZER INC. | AIRSUPRA, Cologuard Collection Kit, ELIQUIS, FREESTYLE LIBRE 3, JARDIANCE, KRYSTEXXA, Kerendia, MOUNJARO, NURTEC ODT, REXULTI, TRELEGY ELLIPTA, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error